Pure Global

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) - Trial NCT06383390

Access comprehensive clinical trial information for NCT06383390 through Pure Global AI's free database. This Phase 3 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Overweight and Obesity. Target enrollment is 10000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06383390
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06383390
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index ≥27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease.

Study Focus

Overweight and Obesity

Retatrutide

Interventional

drug

Sponsor & Location

Eli Lilly and Company

Birmingham,Daphne,Huntsville,Mobile,Anchorage,Paradise Valley,Phoenix,Phoenix,Tucson,Little Rock,Apple Valley,Beverly Hills,Canoga Park,Covina,Escondido,Fountain Valley,La Jolla,Lynwood,Northridge,Pas, Argentina,Australia,Austria,Brazil,Canada,Czech,Denmark,France,Germany,Hungary,India,Israel,Mexico,N

Timeline & Enrollment

Phase 3

May 01, 2024

Feb 01, 2029

10000 participants

Primary Outcome

Time to First Occurrence of Composite Endpoints,Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death

Summary

The main purpose of this study is to determine if retatrutide can significantly lower the
 incidence of serious heart-related complications or prevent the worsening of kidney function.
 The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic
 Cardiovascular Disease and/or chronic kidney disease.

ICD-10 Classifications

Obesity
Other obesity
Obesity due to excess calories
Obesity, unspecified
Obesity and other hyperalimentation

Data Source

ClinicalTrials.gov

NCT06383390

Non-Device Trial